QPX7831

Qpex Biopharma, Inc. · Phase 1 active Small molecule

At a glance

Generic name	QPX7831
Sponsor	Qpex Biopharma, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants (PHASE1)
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment (PHASE1)
Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

QPX7831 CI brief — competitive landscape report
QPX7831 updates RSS · CI watch RSS
Qpex Biopharma, Inc. portfolio CI